What is Ovulation Induction?

Ovulation induction refers to the pharmacological stimulation of ovarian follicular development to achieve ovulation in women with oligo-ovulation or anovulation. It involves targeted manipulation of the hypothalamic–pituitary–ovarian (HPO) axis, either by enhancing endogenous gonadotropin release or administering exogenous gonadotropins.

Physiologically, ovulation requires:

• Pulsatile GnRH secretion from the hypothalamus
• Release of FSH and LH from the anterior pituitary
• Follicular maturation and estradiol production
• Mid-cycle LH surge leading to ovulation

Disruption at any level of this axis can result in anovulation.

When is Ovulation Induction Used?

Ovulation induction protocols are indicated in:

• Chronic anovulation, especially in Polycystic Ovary Syndrome
• WHO Group II ovulatory dysfunction (normogonadotropic anovulation)
• Unexplained infertility
• Hypothalamic dysfunction (selected cases)

WHO classification (frequently tested concept):

• Group I: Hypogonadotropic hypogonadism
• Group II: Normogonadotropic (PCOS)
• Group III: Hypergonadotropic hypogonadism (ovarian failure)

Common Ovulation Induction Protocols

Clomiphene Citrate Protocol

Drug Class: Selective Estrogen Receptor Modulator (SERM)

Clomiphene citrate mechanism:

• Competitive inhibition of estrogen receptors in the hypothalamus
• Removal of negative feedback → ↑ GnRH pulse frequency
• ↑ FSH and LH secretion → follicular recruitment

Standard Protocol:

• Initiation: Day 2–5 of the menstrual cycle
• Dose: 50 mg/day for 5 days
• Escalation: Up to 150 mg/day if no ovulation

Pharmacological Notes:

• Long half-life (~5–7 days)
• Anti-estrogenic peripheral effects

Limitations:

• Endometrial thinning
• Poor cervical mucus
• Risk of luteal phase defect

Letrozole Protocol

Drug Class: Aromatase inhibitor

Letrozole ovulation induction mechanism:

• Inhibits aromatase enzyme → ↓ conversion of androgens to estrogens
• Reduced estrogen levels → loss of negative feedback
• ↑ FSH secretion → folliculogenesis

Protocol:

• Initiation: Day 2–5
• Dose: 2.5–7.5 mg daily for 5 days

Pharmacodynamics:

• Short half-life (~45 hours)
• No persistent anti-estrogenic effect on the endometrium

Clinical Significance:

• Higher ovulation and live birth rates in PCOS
• Improved endometrial receptivity

Gonadotropin Protocol

Drugs Used:

• Recombinant FSH (rFSH)
• Human menopausal gonadotropin (hMG: FSH + LH activity)

Mechanism:

• Direct stimulation of ovarian follicles independent of hypothalamic-pituitary control

Protocols:

• Low-dose step-up: Gradual increase to avoid multifollicular development
• Step-down: High initial dose followed by reduction

Monitoring Requirements:

• Serial transvaginal ultrasonography
• Serum estradiol (E2) levels

Indications:

• Clomiphene-resistant anovulation
• Assisted reproductive techniques

Letrozole vs Clomiphene – Key Differences

The letrozole vs clomiphene comparison is clinically relevant, with letrozole now preferred in PCOS-related anovulation.

Types of Infertility Treatment Drugs

Ovulation induction drugs are categorised as:

1. SERMs: Clomiphene citrate
2. Aromatase inhibitors: Letrozole
3. Gonadotropins: FSH, LH preparations
4. Adjunct therapies:
   • Insulin sensitisers (e.g., metformin)
   • Luteal phase support (progesterone)

Step-by-Step Ovulation Induction Protocol

Patient Selection

• Confirm anovulation
• Assess ovarian reserve (AMH, AFC)
• Exclude:
  • Tubal pathology
  • Severe male factor infertility

Drug Selection

• PCOS → Letrozole
• General anovulation → Clomiphene/Letrozole
• Resistant cases → Gonadotropins

Monitoring

• Follicular tracking starting Day 9–10
• Dominant follicle: 18–20 mm
• Endometrial thickness: ≥7 mm

Trigger & Timing

• Administration of hCG trigger (mimics LH surge)
• Ovulation occurs ~36 hours post-trigger
• Timed intercourse or intrauterine insemination is planned accordingly

Risks and Complications

Ovarian Hyperstimulation Syndrome (OHSS)

• More common with gonadotropins
• Pathophysiology: Increased vascular permeability due to VEGF
• Features: Ascites, enlarged ovaries, hemoconcentration

Multiple Pregnancy

• Clomiphene: Increased twin rate
• Gonadotropins: Higher risk of multifetal gestation

Other Adverse Effects

• Functional ovarian cysts
• Vasomotor symptoms (clomiphene)
• Abdominal discomfort

Ovulation Induction in PCOS Patients

Key pathophysiology:

• Increased LH: FSH ratio
• Hyperandrogenism
• Arrested follicular development

Management principles:

• Letrozole as a first-line agent
• Lifestyle modification (weight reduction improves ovulation)
• Metformin in insulin-resistant individuals

Clomiphene resistance is defined as failure to ovulate at the maximum dosage.

Clinical Tips for Gynaecologists

• Aim for mono-follicular development to reduce complications
• Use the lowest effective dose
• Avoid excessive estradiol rise
• Individualise treatment based on ovarian reserve and BMI

Role of IUI in Ovulation Induction

Ovulation induction is frequently combined with intrauterine insemination to enhance conception rates.

• Indicated in unexplained infertility and mild male factor
• Synchronisation with ovulation improves fertilisation probability

High-Yield Revision Points

• Letrozole = Drug of choice in PCOS ovulation induction 
• Clomiphene = SERM with anti-estrogenic effects 
• Gonadotropins = Highest efficacy but highest risk (OHSS, multiples) 
• Follicle size for trigger = 18–20 mm 
• Clomiphene resistance = No ovulation at 150 mg dose

Ovulation induction protocols form a critical component of infertility management, integrating reproductive physiology with pharmacological intervention. A clear understanding of the clomiphene citrate mechanism, letrozole ovulation induction, and gonadotropin therapy infertility protocols is essential for clinical application and examinations. The transition toward letrozole as a preferred agent, particularly in PCOS, reflects evidence-based evolution in infertility treatment drugs.

NEET PG Pattern Questions:

Q1. The primary mechanism of action of clomiphene citrate is:
A. Direct ovarian stimulation
B. Aromatase inhibition
C. Estrogen receptor blockade in the hypothalamus
D. Progesterone receptor activation

Answer: C. Estrogen receptor blockade in the hypothalamus

Explanation: This increases GnRH secretion, leading to increased FSH and LH.

Q2. Ovulation trigger with hCG is usually given when the dominant follicle reaches:
A. 10–12 mm
B. 12–14 mm
C. 18–20 mm
D. 22–24 mm

Answer: C. 18–20 mm

Q3.Assertion (A): Letrozole is preferred over clomiphene in ovulation induction for PCOS.
Reason (R): Letrozole improves endometrial thickness compared to clomiphene.

1. Both A and R are true, and R explains A
   B. Both A and R are true, but R does not explain A
   C. A is true, R is false
   D. A is false, R is true

Answer: A. Both A and R are true, and R explains A

Q4. Clomiphene citrate is classified as:
A. Aromatase inhibitor
B. Selective estrogen receptor modulator
C. Progesterone analogue
D. GnRH analogue

Answer: B. Selective estrogen receptor modulator

Frequently Asked Questions:

Q1. What is the first-line drug for ovulation induction in PCOS?
 Ans – Letrozole

Q2. What is the mechanism of clomiphene citrate?
 Ans – Estrogen receptor blockade at hypothalamus → ↑ GnRH → ↑ FSH/LH

Q3. Define clomiphene resistance.
 Ans – Failure to ovulate at 150 mg/day

Q4. What is the major complication of gonadotropin therapy?
 Ans – Ovarian Hyperstimulation Syndrome (OHSS)

Q5. What is the ideal follicular size for an ovulation trigger?
 Ans – 18–20 mm

Q6. Why is letrozole preferred over clomiphene?
 Ans – Better endometrial effects and improved ovulation rates